Search Terms
Call us today 212-583-0100
ir@enzo.com
Toggle navigation
Home
Corporate
Investor Information
About Us
Officers & Directors
Press Releases
Careers
Therapeutics
About ENZO Therapeutics
Overview
Our Mission
Our Strategy
Partnering
Maps and Directions
Contact Us
Therapeutic Market
Overview
Inflammatory Bowel Disease
Uveitis
HIV
Bone Disorders
Diabetes
Technologies
Immune Regulation
Gene Technology
Cell Signaling Modulation
Pipeline
Overview
Cell Signaling Modulation
Diabetes
Preclinical Studies for Bone Disorders
Immune Regulation
Alequel ™
Optiquel ™
Gene Technology
Stealth Vector™ HGTV43™
Clinical Labs
Life Sciences
Contact
Section 16 Filings
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Management Team
Presentations
Contacts
FAQ
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Governance Documents
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Filing Type:
View All
3
3/A
4
4/A
5
Year:
View All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
Date
Form
Description
PDF
XBRL
Pages
08/05/03
4
Statement of changes in beneficial ownership of securities
2
07/15/03
4
Statement of changes in beneficial ownership of securities
2
Previous
1…
26
27
28
29
30
31
32
33
34
35
Email Alerts
Tear Sheet
Contacts
RSS News Feed